cell therapy

Manufacturing Challenges & Solutions for Cell Therapy – Managing Complexity Across the Ecosystem

The Supply Chain & Logistics for Cell & Gene Therapies (CGT) Seminar took place on January 20, 2020, in Toronto, Canada. International experts and health care leaders discussed their experiences and solutions to supply chain and logistics challenges for the CGT industry, and shared key considerations for the first and last 100 metres to get a treatment to the clinic. Presenters touched upon global issues, the regulatory environment, how product is received on the clinic floor, and the physician’s experience. The seminar was hosted by CCRM and CellCAN. A live webcast of the presenters and their slides was also offered.

In this video taken from the live webcast, Greg Crescenzi, Enterprise Solutions Leader for Cell & Gene Therapy, GE Healthcare, shares a presentation entitled Overview of Manufacturing Challenges and Solutions for Cell Therapy – Managing Complexity Across the Ecosystem.

For more information about educational events hosted by CCRM, visit the Events page on ccrm.ca.

Considerations for the first 100 m and last 100 m of shipping a cell or gene therapy – the UK solution

In this video taken from the live webcast, Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult, shares a presentation entitled Considerations for the first 100 m and last 100 m of shipping a cell or gene therapy – the UK solution.

For more information about educational events hosted by CCRM, visit the Events page on ccrm.ca.

Connecting Advanced Therapies to Patients Across Canada

In this video taken from the live webcast, Simon Ellison, Cell and Gene Therapy Service Director, World Courier, shares a presentation entitled Connecting Advanced Therapies to Patients Across Canada.

For more information about educational events hosted by CCRM, visit the Events page on ccrm.ca.

The Centre for Cell and Vector Production: a look inside

CCRM, in partnership with University Health Network, has built a Good Manufacturing Practices-compliant facility to produce cells and viral vectors for Phase I and II clinical trials. Now welcoming clients, the Centre for Cell and Vector Production (CCVP) is a 20,000 sq. ft. space featuring ISO Class 7/Grade B cell and viral vector clean rooms – 10 in total. Watch our video for a view into this leading-edge facility and hear from Susan Marlin, of Clinical Trials Ontario, along with others, on why CCVP is so important for Toronto and Canada. Working with academics, cell therapy and gene therapy developers, CCRM is continuing to drive the industry closer to delivering on the promise of regenerative medicine as a possible cure for many devastating diseases and conditions.

The CCVP video, produced by Big Red Oak, has won the 2019 Videographer Award of Excellence (the highest level). The Videographer Awards “recognize works that are written, produced, shot and/or edited in an exceptional manner.” The awards are administered and judged by the international Association of Marketing and Communication Professionals as part of the dotCOMM Awards.

Introducing the Centre for Cell and Vector Production

The Centre for Cell and Vector Production (CCVP) is a leading-edge Good Manufacturing Practices-compliant facility built in partnership with University Health Network. CCVP is located at MaRS, in downtown Toronto, adjacent to some of Canada’s leading hospitals and research institutes. The 20,000 sq. ft. facility includes: 10 suites, two dedicated to viral vectors and eight for cell therapies. They are ISO Class 7/Grade B clean rooms for Phase I and II trials. CCVP is designed for FDA, Health Canada and EMA compliance.

CCRM Sits Down with Stephen Minger

Dr. Stephen Minger is Global Head of Research and Development for the Cell Technologies business of GE Healthcare Life Sciences and, in this role, Dr. Minger travels the world to stay current and connected with what’s happening in the regenerative medicine industry. He shares his thoughts about the industry in this video.

Dr. Minger leads the development of GE Healthcare Life Sciences’ cell-based technologies for use in drug discovery and pharmaceutical research. He also directs the development of GE Healthcare Life Sciences’ enabling technologies for the rapidly emerging field of regenerative medicine and cell therapy.